Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198423 | 0.82 | KDM4E (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL7204475 | 0.79 | GRM4 (0.31) | GRM4 | |
| SCHEMBL11404798 | 0.77 | CYP1A2 (0.45) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL11481457 | 0.76 | RNPEP (0.31) | — | |
| SCHEMBL7198413 | 0.76 | MEN1 (0.39) | MEN1ALDH1A1CYP1A2THRBKMT2A | |
| SCHEMBL16587608 | 0.76 | — | — | |
| SCHEMBL4813122 | 0.75 | ODC1 (0.47) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL4813109 | 0.75 | ODC1 (0.47) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL4813114 | 0.75 | ODC1 (0.47) | ARG1ARG2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL7204001 | 0.75 | GABRP (0.41) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | GGT1 547/4885GRM4 3887/4885ARG1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.